| Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics. | |
| | |
MedLine Citation:
|
PMID: 20658795 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: The ADNI (Alzheimer's Disease Neuroimaging Initiative) is a large longitudinal study of patients with probable Alzheimer's disease (AD), patients with mild cognitive impairment (MCI) and healthy elderly controls followed for at least 2-3 years. Many participants in the ADNI are being treated with medications, and these may have beneficial or deleterious effects. OBJECTIVE: The goal of the study was to characterize baseline medication use in the ADNI. METHODS: Diagnosis, demographics, medication status, psychometric data and MRI measures of hippocampal volume and entorhinal cortex thickness were obtained for 818 participants from the ADNI cohort. Total number of medications, Beers list (potentially dangerous) medications and AD treatments were also tabulated. ANOVA and logistic regression were used to assess associations between baseline pharmacotherapy and diagnosis, demographics, and selected clinical and MRI variables. RESULTS: Of the 818 enrolled ADNI participants, 809 were available for analysis in the present study, including 184 patients with AD, 399 patients with MCI and 226 healthy elderly controls. Significant gender differences in recruitment were observed in the MCI group. The average number of medications per participant was 8 (SD 4) and 22% reported treatment with one or more Beers list medications. For symptomatic treatment of MCI or AD, donepezil and memantine were the most commonly reported drugs. As expected, MCI and AD patients with more severe impairment were more likely to be treated. Men received treatment more frequently than women. Older subjects and those with less education were less likely to receive treatment. CONCLUSIONS: AD and MCI participants from the ADNI cohort were being treated with polypharmacy and many were also taking one or more medications with the potential for adverse effects. Off-label use of cholinesterase inhibitors and/or memantine for MCI was common, with more severely affected patients most likely to receive treatment. Differences in the frequency of symptomatic treatment were also observed as a function of age, years of education, gender and disease severity. |
| | |
Authors:
|
Noam U Epstein; Andrew J Saykin; Shannon L Risacher; Sujuan Gao; Martin R Farlow; |
Related Documents
:
|
2060155 - Antimalarial medications in dermatology. a review. 6540815 - Treatment of girls with urethral prolapse. 9729705 - Diagnosis and treatment of an adolescent with comorbid type 1 diabetes mellitus and ano... 16625845 - Can treatment with somatostatin analogs replace neurosurgery? 11315465 - New york chapter history of military medicine award. u.s. army medical helicopters in t... 10527345 - Should new south wales hospital disaster teams be sent to major incident sites? |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Drugs & aging Volume: 27 ISSN: 1170-229X ISO Abbreviation: Drugs Aging Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-27 Completed Date: 2010-11-08 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 9102074 Medline TA: Drugs Aging Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 677-86 Citation Subset: IM |
Affiliation:
|
Indiana University School of Medicine, Indianapolis, 46202, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Alzheimer Disease / drug therapy*, pathology Cognition Disorders / drug therapy Entorhinal Cortex / pathology Female Hippocampus / pathology Humans Magnetic Resonance Imaging / methods* Male Middle Aged Nootropic Agents / therapeutic use* Polypharmacy Sex Characteristics |
| Grant Support | |
ID/Acronym/Agency:
|
P30 AG010133-18S1/AG/NIA NIH HHS; P30 AG10133/AG/NIA NIH HHS; R01 AG019771-10/AG/NIA NIH HHS; R01 AG19771/AG/NIA NIH HHS; R03 EB008674/EB/NIBIB NIH HHS; R03 EB008674-01S1/EB/NIBIB NIH HHS; U01 AG024904/AG/NIA NIH HHS; U01 AG024904-01/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Nootropic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the Netherlands: A...
Next Document: Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs?